HKG:9606

3 stories mentioning HKG:9606Updated just now

Every FINWIRES story that references HKG:9606, newest first.

Duality Biotherapeutics Ties Up With Genentech to Develop Oncology Drugs

Duality Biotherapeutics (HKG:9606) partnered with Roche Group's Genentech to develop oncology drugs based on the DualityBio Unique Payload Antibody Conjugate platform, according to a Friday disclosure on the Hong Kong bourse.The Hong Kong-listed biotherapy company will receive an upfront payment of $45 million as part of the deal, as well as milestone payments of over $1 billion.Duality will also receive tiered royalty payments on annual net sales of products approved from the partnership.

HKG:9606

Asia74d ago

Duality Biotherapeutics Advances Shanghai STAR Market Listing Plan

Duality Biotherapeutics (HKG:9606) said the Shanghai Stock Exchange accepted the application materials for the proposed share issue and listing on the Science and Technology Innovation Board, according to a Friday Hong Kong bourse filing.Shares of the biotechnology company were up over 3% in Monday's late-morning trade.

HKG:9606

Asia100d ago

Duality Biotherapeutics Launches $40 Million Stock Buyback; Shares Rise 3%

Duality Biotherapeutics (HKG:9606) announced plans to buy back up to $40 million worth of its shares from the open market, according to a Tuesday filing with the Hong Kong bourse.The biopharmaceutical firm's shares gained over 3% in morning trade on Wednesday.The company said its current share price does not reflect its intrinsic value, representing a good opportunity to conduct the buyback.Meanwhile, Duality Bio Chairman and Chief Executive Officer Zhu Zhongyuan plans to increase his shareholding in the company by spending up to $5 million to buy shares in the secondary market.

HKG:9606

Track with the FINWIRES app suite

FolioX

Track HKG:9606 in your portfolio

WheelAI

Analyze HKG:9606 options with the wheel strategy

StockInsider

See market sentiment on HKG:9606